文献速递外周动脉疾病

股腘动脉药物涂层球囊血管成形术中血管准备后残余狭窄小于50%的影响

Impact of a Less Than 50% Residual Stenosis Following Vessel Preparation in Femoropopliteal Drug-Coated Balloon Angioplasty.
PubMed 文献 · J Endovasc Ther · 2024-01-09

这项回顾性研究纳入2018年3月至2019年12月间268例(308条肢体)因症状性下肢动脉疾病接受股腘动脉药物涂层球囊介入治疗的患者,评估成功血管准备(残余狭窄<50%且夹层分级<D级)的临床影响。中位随访2.1年,成功血管准备组163例(60.8%),其一期通畅率和免于临床驱动靶病变血运重建率均显著高于非成功组(54.2% vs 33.0%,p<0.001;69.9% vs 57.7%,p=0.047)。多因素分析显示成功血管准备和预球囊直径与参考血管直径比值与一期通畅率独立相关。

要点

  • 成功血管准备(残余狭窄<50%且夹层<D级)与DCB股腘动脉介入后一期通畅率独立相关
  • 成功血管准备组一期通畅率54.2% vs 非成功组33.0%(p<0.001)
  • 成功血管准备组免于CD-TLR率69.9% vs 非成功组57.7%(p=0.047)

核心结论

  • 在DCB股腘动脉介入前实现成功血管准备与一期通畅率独立相关。
  • 预球囊直径与参考血管直径比值也与一期通畅率独立相关。
  • 当仅在DCB治疗前实现成功血管准备时,高剂量DCB与低剂量DCB的中期临床结局相当。
  • 为最大化DCB疗效,成功血管准备在日常临床实践中非常重要。

研究设计与样本

  • 回顾性研究,纳入2018年3月至2019年12月间268例(308条肢体)因症状性下肢动脉疾病接受股腘动脉DCB介入治疗(未使用斑块旋切装置)的患者。
  • 高剂量DCB占69.8%,低剂量DCB占30.2%。
  • 成功血管准备定义为DCB前残余狭窄<50%且夹层分级<D级(成功血管准备组)。
  • 主要结局指标为一期通畅率,并评估其相关因素。

主要发现

  • 中位随访2.1年(四分位距=1.1-2.7年)。
  • 成功血管准备在163例患者中实现(60.8%)。
  • 成功血管准备组一期通畅率54.2% vs 非成功组33.0%(p<0.001)。
  • 成功血管准备组免于CD-TLR率69.9% vs 非成功组57.7%(p=0.047)。
  • 在成功血管准备组,高剂量DCB与低剂量DCB的一期通畅率(53.2% vs 53.6%,p=0.48)和免于CD-TLR率(68.7% vs 70.9%,p=0.69)相当。

关键数值与推荐

  • 成功血管准备定义为DCB前残余狭窄<50%且夹层分级<D级。

临床怎么用

  • 为最大化DCB疗效,成功血管准备在日常临床实践中非常重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Drug-coated balloon (DCB) has been established as first-line therapy in femoropopliteal (FP) intervention, and successful vessel preparation (VP) is considered a key element. However, the clinical impact of successful VP remains unknown. This retrospective study examined the clinical impact of successful VP in DCB FP intervention. METHODS: In total, 268 patients (308 limbs) who underwent successful FP intervention using DCB without atherectomy devices for symptomatic lower extremity artery disease between March 2018 and December 2019 were included in this study (high-dose DCB: 69.8%; low-dose DCB: 30.2%). Successful VP was defined as <50% residual stenosis and <dissection grade D before DCB (the successful VP group). The primary outcome measure was primary patency, and its associated factors were evaluated. RESULTS: The median follow-up period was 2.1 (interquartile range=1.1-2.7) years. Successful VP was achieved in 163 patients (60.8%). Primary patency and freedom from clinically-driven target lesion revascularization (CD-TLR) were significantly higher in the successful VP group than in the nonsuccessful VP group (54.2% vs 33.0%, p<0.001; 69.9% vs 57.7%, p=0.047). In the successful VP group, high-dose DCB and low-dose DCB were comparable in primary patency and freedom from CD-TLR (53.2% vs 53.6%, p=0.48; 68.7% vs 70.9%, p=0.69). In nonsuccessful VP group, high-dose DCB demonstrated numerically higher primary patency but not statistically significant than low-dose DCB (44.5% vs 16.0%, p=0.06), whereas no significant difference in freedom from CD-TLR was observed (56.0% vs 58.9%, p=0.29). On multivariate analysis, successful VP and preballoon size to reference vessel diameter ratio were significantly associated with primary patency. CONCLUSIONS: Achieving successful VP before DCB was independently associated with primary patency in DCB FP intervention.Clinical ImpactThis study revealed that the successful vessel preparation (VP) before DCB and preballoonsize to reference vessel diameter ratio were independently associated with primary patency in DCB femoropopliteal intervention. When successful VP was achieved only before DCB treatment, the clinical outcomes were comparable between high-dose DCB and low-dose DCB at midterm follow-up.To maximized DCB efficacy, successful VP is very important in daily clinical practice.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tomoi Y, Soga Y, Imada K, et al. Impact of a Less Than 50% Residual Stenosis Following Vessel Preparation in Femoropopliteal Drug-Coated Balloon Angioplasty. J Endovasc Ther. 2024. PMID: 38193398. doi:10.1177/15266028231223086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。